Short Communication
Volume 8 Issue 8 - 2021
High Cost Drugs a worldwide Issue Resolved in Mexico by the IMSS: Catalog II a Model to Follow
Morelos Adolfo García Sánchez1*, Ramón Armando Sánchez Tamayo1, Oswaldo Díaz González1, Mireya De La Fuente González2, Luis Andres Saenz Romero5, Elizabeth Mendoza Portillo3, María Isabel Estrada Rodríguez4, María De Los Ángeles Carmona Alva5, Imelda Yasmín Palma Cortés5, Daniel Pérez Nuñez5, Roxana Islas Mendoza5, Diego Enrique Martínez Castañeda5 and José Juan Lozano Nuevo6
1Medical Specialist, Coordinator of Medical Programs, Institutional Division of Basic Tables and Supplies for Health, Mexican Social Security Institute, National Autonomous University of Mexico, México City, Mexico
2General Surgeon, Surgical Department at “Dr. Gaudencio González Garza” General Hospital Specialized Medical Unit, “La Raza”, National Medical Center, Mexican Social Security Institute, National Autonomous University of Mexico, México City, México
3Internal Medicine and Critical Medicine Care, Intensive Care Unit Department at “Dr. Rubén Leñero” General Hospital Secretary of Health of Mexico City, National Autonomous University of Mexico, México City, Mexico
4Pediatrist, Pediatrician Department, Regional General Hospital No. 251, Metepec, Mexican Social Security Institute, National Autonomous University of Mexico, México State, México
5General Surgeon, Surgical Department at “Dr. Rubén Leñero” General Hospital Secretary of Health of Mexico City, National Autonomous University of Mexico, México City, México
6Internal Medicine, Internal Medicine Department at “Ticomán” General Hospital Secretary of Health of Mexico City, National Autonomous University of Mexico, México City, México
*Corresponding Author: Morelos Adolfo García Sánchez, Colonic and Rectal Surgeon and General Surgeon, Medical Specialist, Coordinator of Medical Programs, Institutional Division of Basic Tables and Supplies for Health, Mexican Social Security Institute, National Autonomous University of Mexico, México City, Mexico.
Received: June 24, 2021; Published: July 19, 2021




Historically, drugs are stigmatized in the history of medicine; where all civilization to date, makes use of superstition and the fable of diseases in their cure to divine causes. The great milestones of human history focuses on fighting disease and living longer in the best health conditions; that after centuries of efforts, successes and errors, medicine has experienced in recent decades an advance of such caliber that it has made it possible. The oldest form of pharmacology is documented in China Pentsao, attributed to the works ordered by Emperor Shemmeng 2,697 years BC. C. he codified more than 350 herbs that included medicinal plants like ginger, aconite, pomegranate root, rhubarb, opium, minerals like mercury, sulfur and arsenic [1]. The Ebers papyrus, 3,000 to 1,500 BC. C. describes a recipe mix for 700 substances, some in use today [2].

References

  1. Fernández-Arguelles RA y cols. “Apuntes para la historia de los medicamentos y la farmacia”. Nueva Época17 (2014): 59-63.
  2. Errecalde OJ. “La evolución del medicamento en la Historia”. Anales 65 (2004): 327-365.
  3. Moral CP. “Historia de la Farmacia. Los medicamentos, la riqueza y el bienestar", de Joan Esteva de Sagrera”. Revista Enfermería Global 8 (2006): 1-3.
  4. Godínez-Reséndiz R and y Aceves-Pastrana P. “El surgimiento de la industria farmacéutica en México (1917-1940)”. Revista Mexicana de Ciencias Farmacéuticas12 (2014): 55-66.
  5. Organización Panamericana de la Salud. Área de Tecnología, Atención de la Salud e Investigación Proyecto de Medicamentos Esenciales y Productos Biológicos (THR/EM) El acceso a los medicamentos de alto costo en las Américas: contexto, desafíos y perspectivas. DC (2009).
  6. Lasalvia P., et al. “International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review”. Expert Review of Pharmacoeconomics and Outcomes Research4 (2019): 409-420.
  7. Mincarone P., et al. “Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements”. Public Health Genomics1 (2017): 1-8.
  8. Korchagina D., et al. “Orphan Drugs in Oncology”. Recent Results in Cancer Research 213 (2019): 109-142.
  9. Zhao M and Wei DQ. "Rare Diseases: Drug Discovery and Informatics Resource”. Interdisciplinary Sciences: Computational Life Sciences1 (2018): 195-204.
  10. Jayasundara K., et al. “Estimating the clinical cost of drug development for orphan versus non-orphan drugs”. Orphanet Journal Of Rare Diseases1 (2019): 12.
  11. Charbonneau M and Gagnon MA. "Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs”. Health Policy12 (2018): 1295-1301.
  12. Wonders KY., et al. “Cost Savings Analysis of Individualized Exercise Oncology Programs”. Integrative Cancer Therapies 18 (2019): 1534-1573.
  13. Aguiar PN Jr., et al. “In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments”. Value in Health Regional Issues 20 (2019): 47-50.
  14. Tay-Teo K., et al. “Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies”. JAMA Network Open 1 (2019): 68-75.
  15. Morelos Adolfo García Sánchez., et al. “Colon Cancer and Rectum. A Critical Problem in Mexico”. EC Gastroenterology and Digestive System 4 (2021): 104-116.
  16. D'Amico F., et al. “Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group”. Digestive and Liver Disease 2 (2020): 138-142.
  17. Michielsens CAJ., et al. “Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial”. Trials 1 (2020): 90.
  18. Kunnumakkara AB., et al. “Cancer drug development: The missing links”. Experimental Biology and Medicine 8 (2019): 663-689.
  19. Bender E. "Cost of Cancer Drugs: Something Has To Give”. Managed Care5 (2018): 18-22.
  20. De Oliveira RTG., et al. “Socioeconomic impact of high-cost drugs in Brazilian dermatology. Legal and financial aspects, and impact on clinical practice”. Anais Brasileiros de Dermatologia2 (2021): 200-209.
  21. Aleman A and Perez Galan A. "Impact Of Health Technology Assessment In Litigation Concerning Access To High-Cost Drugs”. International Journal of Technology Assessment in Health Care4 (2017): 411-414.
  22. Schleicher SM., et al. “Medication overuse in oncology: current trends and future implications for patients and society”. Lancet Oncology4 (2018): 200-208.
  23. Aggarwal A., et al. “Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund”. Annals of Oncology8 (2017): 1738-1750.
  24. Lasalvia P., et al. “International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review”. Expert Review of Pharmacoeconomics and Outcomes Research4 (2019): 409-420.
  25. Morrell L., et al. “Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals”. BMC Health Services Research1 (2018): 393.
  26. Altice CK., et al. “Financial Hardships Experienced by Cancer Survivors: A Systematic Review”. Journal of the National Cancer Institute 45 (2017): 1-9.
  27. Rawson NSB. "National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare”. International Journal of Health Policy and Management12 (2020): 524-527.
  28. Baudouin A., et al. “[Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital]”. Bulletin du Cancer6 (2017): 538-551.
  29. Sopelsa M., et al. “Pharmacotherapeutic profile of users and expenditure on high-cost drugs in Sao Leopoldo, Rio Grande do Sul State, Brazil, 2014”. Epidemiologia e Servicos de Saude4 (2017): 759-770.
  30. Hwang TJ., et al. “Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs”. JAMA Internal Medicine3 (2019): 374-380.
  31. Padula WV., et al. “Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry”. Applied Health Economics and Health Policy6 (2018): 753-763.
  32. Pereira LC., et al. “Challenges in the Regulation of High-Cost Treatments: An Overview From Brazil”. Value in Health Regional Issues 20 (2019): 191-195.
  33. Kennedy J., et al. “Unfilled Prescriptions of Medicare Beneficiaries: Prevalence, Reasons, and Types of Medicines Prescribed”. Journal of Managed Care and Specialty Pharmacy8 (2020): 935-942.
  34. Vokinger KN., et al. “Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis”. Lancet Oncology5 (2020): 664-670.
  35. Salmasi S., et al. “Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region”. BMC Cancer1 (2017): 903.
  36. Bentley C., et al. “Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada”. BMC Health Services Research1 (2018): 339.
  37. Karikios DJ., et al. “Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia”. Internal Medicine Journal 4 (2017): 400-407.
  38. Kashyap A., et al. “Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India”. Expert Review of Pharmacoeconomics and Outcomes Research 4 (2020): 355-361.
  39. Valido A., et al. “Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center”. Acta Reumatologica Portuguesa 4 (2019): 303-311.
  40. Gonzalez-Fernandez M., et al. “Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price”. International Journal of Clinical Pharmacy 6 (2018): 1528-1538.
  41. Braun J and Kay J. "The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis”. Expert Opinion on Drug Safety 3 (2017): 289-302.
  42. Ingrasciotta Y., et al. “Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy”. Biodrugs4 (2019): 345-352.
  43. D'Amico F., et al. “Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group”. Digestive and Liver Disease2 (2020): 138-142.
  44. Zinzani PL., et al. “Are Biosimilars the Future of Oncology and Haematology?”. Drugs15 (2019): 1609-1624.
  45. Hubel K., et al. “Biosimilars in oncology: Effects on economy and therapeutic innovations”. European Journal of Cancer 139 (2020): 10-19.
  46. Ghabri S., et al. “Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France”. Value in Health3 (2020): 461-470.
  47. Birkner B., et al. “Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis”. Plos One 1 (2020): e0226754.
  48. Michielsens CAJ., et al. “Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial”. Trials 1 (2020): 90.
  49. http://reposipot.imss.gob.mx/normatividad/DNMR/Procedimiento/2450-003-011.pdf
Citation: Morelos Adolfo García Sánchez., et al. “High Cost Drugs a worldwide Issue Resolved in Mexico by the IMSS: Catalog II a Model to Follow” EC Gastroenterology and Digestive System 8.8 (2021): 47-52.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


July Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the July issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before August 09, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk